Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors

J Proska and S Tucek

Institute of Physiology, Academy of Sciences of the Czech Republic, Prague.

Kinetics of the interactions between the neuromuscular blocker alcuronium, the specific muscarinic antagonist N-[methyl-3H] methyl scopolamine ([3H]NMS), and muscarinic receptors were investigated in homogenates of rat heart atria. Two effects of alcuronium on the binding of [3H]NMS could be distinguished. (a) Alcuronium concentration- dependently slowed the association of [3H]NMS with receptors and the dissociation of [3H]NMS from receptors so that, at high alcuronium concentrations, equilibrium binding could not be reached, even after 20 hr, without special precautions. (b) Alcuronium increased the affinity of receptors for [3H]NMS, which was manifested by a decrease of the apparent Kd (> 3-fold) with no change in the Bmax for [3H]NMS binding. The effects of alcuronium on the rates of [3H]NMS association and dissociation can be explained only by a reaction mechanism in which [3H]NMS binds only to free receptors (not occupied by alcuronium), whereas alcuronium binds both to free receptors and to receptors occupied by [3H]NMS. Similarly, [3H]NMS cannot dissociate from receptors as long as alcuronium is attached to them. Experimental data agree with corresponding mathematical models. It is proposed that alcuronium blocks entry to the pocket containing the [3H]NMS binding site. In addition to this blocking effect, alcuronium has a positive allosteric effect on [3H]NMS binding, presumably by inducing a conformational change of the orthosteric muscarinic binding site. Earlier observations suggesting that, at high concentrations, alcuronium also competes for [3H]NMS binding sites can be explained by insufficient equilibration of the system.

Volume 45, Issue 4, pp. 709-717, 04/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				A. Zahradnikova, I. Minarovic, and I. Zahradnik Competitive and Cooperative Effects of Bay K8644 on the L-Type Calcium Channel Current Inhibition by Calcium Channel Antagonists J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 638 - 645. [Abstract] [Full Text] [PDF]

				A. A. Lanzafame, P. M. Sexton, and A. Christopoulos Interaction Studies of Multiple Binding Sites on M4 Muscarinic Acetylcholine Receptors Mol. Pharmacol., August 1, 2006; 70(2): 736 - 746. [Abstract] [Full Text] [PDF]

				J. Jakubik, A. Krejci, and V. Dolezal Asparagine, Valine, and Threonine in the Third Extracellular Loop of Muscarinic Receptor Have Essential Roles in the Positive Cooperativity of Strychnine-Like Allosteric Modulators J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 688 - 696. [Abstract] [Full Text] [PDF]

				V. Avlani, L. T. May, P. M. Sexton, and A. Christopoulos Application of a Kinetic Model to the Apparently Complex Behavior of Negative and Positive Allosteric Modulators of Muscarinic Acetylcholine Receptors J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1062 - 1072. [Abstract] [Full Text] [PDF]

				A. Christopoulos and T. Kenakin G Protein-Coupled Receptor Allosterism and Complexing Pharmacol. Rev., June 1, 2002; 54(2): 323 - 374. [Abstract] [Full Text] [PDF]

				A. Krejci and S. Tucek Changes of Cooperativity between N-Methylscopolamine and Allosteric Modulators Alcuronium and Gallamine Induced by Mutations of External Loops of Muscarinic M3 Receptors Mol. Pharmacol., October 1, 2001; 60(4): 761 - 767. [Abstract] [Full Text] [PDF]

				J. Ellis and M. Seidenberg Interactions of Alcuronium, TMB-8, and Other Allosteric Ligands with Muscarinic Acetylcholine Receptors: Studies with Chimeric Receptors Mol. Pharmacol., April 13, 2001; 58(6): 1451 - 1460. [Abstract] [Full Text]

				A. L. Gnagey, M. Seidenberg, and J. Ellis Site-Directed Mutagenesis Reveals Two Epitopes Involved in the Subtype Selectivity of the Allosteric Interactions of Gallamine at Muscarinic Acetylcholine Receptors Mol. Pharmacol., December 1, 1999; 56(6): 1245 - 1253. [Abstract] [Full Text]

				J. Jakubík and T. Haga Effects of an Agonist, Allosteric Modulator, and Antagonist on Guanosine-gamma -[35S]thiotriphosphate Binding to Liposomes with Varying Muscarinic Receptor/Go Protein Stoichiometry Mol. Pharmacol., November 1, 1998; 54(5): 899 - 906. [Abstract] [Full Text]

				A. Christopoulos, T. L. Pierce, J. L. Sorman, and E. E. El-Fakahany On the Unique Binding and Activating Properties of Xanomeline at the M1 Muscarinic Acetylcholine Receptor Mol. Pharmacol., June 1, 1998; 53(6): 1120 - 1130. [Abstract] [Full Text]

				C. Tränkle, I. Andresen, G. Lambrecht, and K. Mohr M2 Receptor Binding of the Selective Antagonist AF-DX 384: Possible Involvement of the Common Allosteric Site Mol. Pharmacol., February 1, 1998; 53(2): 304 - 312. [Abstract] [Full Text]

				A. Lanzafame, A. Christopoulos, and F. Mitchelson Three Allosteric Modulators Act at a Common Site, Distinct from that of Competitive Antagonists, at Muscarinic Acetylcholine M2 Receptors J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 278 - 285. [Abstract] [Full Text]

				J. Jakubík and E. E. El-Fakahany Positive Cooperativity of Acetylcholine and Other Agonists with Allosteric Ligands on Muscarinic Acetylcholine Receptors Mol. Pharmacol., July 1, 1997; 52(1): 172 - 179. [Abstract] [Full Text]